Compartilhar
Informação da revista
Vol. 45. Núm. S3.
XIV Eurasian Hematology Oncology Congress
Páginas S35-S36 (outubro 2023)
Vol. 45. Núm. S3.
XIV Eurasian Hematology Oncology Congress
Páginas S35-S36 (outubro 2023)
PP 09
Acesso de texto completo
CHARACTERIZATION AND MANAGEMENT OF PATIENTS WITH HEREDITARY FACTOR X DEFICIENCY: A RETROSPECTIVE SINGLE CENTER EXPERIENCE
Visitas
951
Nigar Abdullayeva1, Fahri Sahin1, Zuhal Demirci1, Bahar Sevgili1
1 Ege University Medical Faculty Hospital Adult Hemophilia and Thrombosis Center, Izmir, Turkey
Este item recebeu
Informação do artigo
Resume
Texto Completo
Baixar PDF
Estatísticas
Tabelas (1)
Tabelas
Suplemento especial
Este artigo faz parte de:
Vol. 45. Núm S3

XIV Eurasian Hematology Oncology Congress

Mais dados
Objective

Factor X deficiency (FXd) is a rare coagulation disorder that can be either hereditary or acquired.

Case report

We characterized patients with FXd and evaluated their bleeding patterns and treatment strategies.

Methodology

This retrospective review includes patients with FXd managed at Ege University Medical Faculty Hospital Ege Adult Hemophilia and Thrombosis Center.

We analyzed demographic characteristics, laboratory results, bleeding scores, and treatments of five patients with FXd (Table).

Patient 1 was admitted for further evaluation of menometrorrhagia and prolonged postpartum bleeding. She required treatment following birth, tooth extraction, and fractional curettage during follow-up. Coagulation tests were run as a part of in vitro fertilization in patient 2 and were abnormal. Family history was significant for a history of thrombosis in her mother. Blood tests were positive for Prothrombin 20210 G/A heterozygous mutation and lupus anticoagulants. The patient has never had any bleeding episodes in the follow-up. Patient 3 has a history of menometrorrhagia, gingival bleeding, and prolonged bleeding after an abortion. The sister of the patient has FXd. In follow-up, she was treated for subcutaneous hematoma, gingival, and post-cesarean bleeding. Patient 4 presented for evaluation of menometrorrhagia. She was treated for polypectomy, two cesarean sections, tooth extraction, intermittent recurrent ecchymosis, and epistaxis. Patient 5 was diagnosed at age one and was referred to us for further management of his condition. His initial presentation was consistent with subdural hematoma. In the follow-up, he was treated for epistaxis, hematuria, subcutaneous hematoma, and gastrointestinal and gingival bleeding. He continues to take Factor X concentrate prophylactically. All the patients are currently healthy and regularly follow up in our center.

Results

Conclusion

Since there is no FX concentrate in our country yet, FFP is used. Patients should be treated with the appropriate FX preparation and a prophylactic approach should be applied in necessary patients.

Texto Completo

Table. Patient Characteristics and Diagnostic Laboratory Results

Patient No  Age at analysis  Gender  FX %  PT sec 10.9-14.7  PTT sec 22.5-31.3  Bleeding score*  Treatment 
1.  41  0.2  60.4  64.1  11  FFP, ES, PCC 
2.  25  12.3  31.5  57.9  Not need 
3.  18  0.8  37  19.3  11  FFP, ES, PCC 
4.  34  34.4  13.9  28.3  15  FFP 
5.  180  138  10  FFP, FXC, PCC 

*- International Society for Thrombosis and Hemostasis/Scientific and Standardization Committee Bleeding Assessment Tool (ISTH-BAT), FFP- fresh frozen plasma, ES- erythrocyte suspension, PCC- prothrombin complex concentrate, FXC- Factor X concentrate, F-female, M-Male

Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas